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Abstract
Background:  Serous epithelial ovarian tumors can be subdivided into benign (BOV), low
malignant potential (LMP) or borderline and invasive (TOV) tumors. Although the molecular
characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive
immunohistochemical markers to distinguish between these tumor types have not been defined.
Methods: In the present study, we used a tissue array composed of 27 BOVs, 78 LMPs and 23 LG
TOVs to evaluate the protein expression of a subset of selected candidates identified in our
previous studies (Ape1, Set, Ran, Ccne1 and Trail) or known to be implicated in epithelial ovarian
cancer disease (p21, Ccnb1, Ckd1).
Results: Statistically significant difference in protein expression was observed for Ccnb1 when
BOV tumors were compared to LMP tumors (p = 0.003). When BOV were compared to LG TOV
tumors, Trail was significantly expressed at a higher level in malignant tumors (p = 0.01). Expression
of p21 was significantly lower in LG tumors when compared with either BOVs (p = 0.03) or LMPs
(p = 0.001). We also observed that expression of p21 was higher in LMP tumors with no (p = 0.02)
or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants.
Conclusion: This study represents an extensive analyse of the benign and highly differentiated
ovarian disease from an immunohistochemical perspective.
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Background
Tumors of the ovary represent a large, heterogeneous and
complex group of neoplasms. The majority of these
tumors are derived from ovarian surface epithelial cells,
from epithelial inclusion cysts confined in the stroma or
from the epithelium of the fallopian tube [1,2]. Epithelial
ovarian tumors present as different histopathology sub-
types among which the serous subtype is the most fre-
quent [reviewed in [3,4]].
Serous tumors can be subdivided into benign (BOV), bor-
derline or low malignant potential (LMP) and invasive
(TOV) tumors. BOV tumors are characterized by epithelial
proliferation without any stratification of cells. LMP
tumors are distinguished from their benign counterpart
by the complexity of their architecture and the presence of
epithelial budding. LMP tumors show a pluristratified
proliferation of the epithelium. LMP tumor cells exhibit
some nuclear atypia and show a higher mitotic activity
when compared to BOV [reviewed in [5-9]].
In contrast to BOV and LMP tumors, TOVs have the capa-
bility of invading the ovarian stroma. TOV tumor cells
present severe nuclear atypia and show high mitotic index
which usually increase with tumor grade. According to the
FIGO criteria, EOCs are graded according to degree of
tumor differentiation: LMPs (referred to as grade 0, G0)
while TOVs are separated in well (grade 1, G1, low grade,
LG), moderately (grade 2, G2), and poorly differentiated
tumors (grade 3, G3) [10,11]. However, several papers
now support a two-tiered classification that separate inva-
sive tumors into low (G1) and high (G2 and G3) grades
[12-14]. Clinical staging in epithelial ovarian cancer
(EOC) varies from stage I to IV. Stage I represents disease
limited to one or both ovaries, stage II is associated with
pelvic extension, stage III spreads into the abdominal cav-
ity and stage IV presents distant metastases [reviewed in
[11,15]].
A major problem with the diagnosis of a serous LMP
tumor is that the absence of stromal invasion is the only
feature that distinguishes them from invasive LG TOV
tumors. The papilla of LMP serous tumors can be deeply
invaginated in the stroma leaving doubt on the presence
of invasion and can be dependant on the serial tissue sec-
tion analyzed. In a subgroup of LMP tumors (10–15%),
the presence of microinvasion is observed and consists of
foci of invasive carcinoma in the ovarian stroma with a
diameter smaller than 3 mm and covering a maximum
surface area of 10 mm2 [7,9,16-23]. Microinvasion does
not appear to impact on patient prognosis
[7,18,19,24,25]. LMP tumors may exhibit a specific archi-
tecture designated micropapillary serous carcinoma
(MPSC) which is characterized by long and thin papilla
(five times longer than larger) without hierarchical
branching [26] [and reviewed in [19]]. Controversy per-
sists as to the association of MPSC with a worse patient
prognosis [26] [and reviewed in [19]]. A portion of LMP
tumors are associated with peritoneal implants of epithe-
lial or desmoplasic type. These implants are also charac-
terized by their invasiveness. Invasive peritoneal implants
are associated with a worse prognosis to LMP patients
compared to the non-invasive implants [27,28].
From a clinical point of view, a diagnosis of serous BOV
tumors does not interfere with survival. LMP tumors are
also indolent and over 95% of LMP patients are still alive
five years after their diagnosis. TOV tumors are the most
lethal with only 30% of the patients surviving beyond five
years. Patients diagnosed with a BOV or a low stage (SI-
SII) LMP tumor undergo a conservative treatment based
on the surgical removal of their tumor. The standard treat-
ment regimen for advanced stage (SIII) LMP of high
relapse risk and TOV patients is maximal cytoreduction
followed by a platinium-taxane based chemotherapy
[reviewed in [7,24]].
The relationship between serous BOV, LMP and LG TOV
tumors at the molecular level remains unclear. Indeed, it
has been suggested that the LMP class of tumors should be
abolished and these tumors be subdivided into BOVs
(LMP with typical architecture and/or non-invasive
implants) and TOVs (LMP with MPSC architecture and/or
invasive implants) [29], although this suggestion has not
gained wide acceptance [19].
We previously identified candidate proteins differentially
expressed between serous LMP and TOV tumors of vari-
ous grades [30-32]. However, due to their rarity, LG
tumors, were not well represented. Nonetheless, encour-
aging results were obtained for Ape1, Set, Trail, Ccne1 and
Ran in their ability to discriminate LMP tumors. In the
present study, our goal was to gain insight into the molec-
ular relationship of BOVs, LMPs and LG TOVs. To this
end, we constructed a tissue array composed of 27 BOVs,
78 LMPs and 23 TOVs of LG (Table 1) and evaluated pro-
tein expression of our previously identified candidates as
well as three other EOC candidates (Ccnb1, Cdk1 and
p21) identified in published microarray analyses which
compared LMP and TOV tumors [33-36].
Methods
Patients and tissue specimens
Tumor samples were collected from patients who under-
went surgery in the Division of Gynecologic Oncology at
the Centre hospitalier de l'Université de Montréal
(CHUM), the Centre hospitalier de l'Hôtel-Dieu de
Québec (CHUQ) or the Centre hospitalier de l'Université
de Sherbrooke (CHUS). The study was approved by the
CHUM institutional ethics committee and written con-BMC Cancer 2008, 8:346 http://www.biomedcentral.com/1471-2407/8/346
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sent was obtained from patients prior to sample collec-
tion. Disease staging as defined by the Federation
International of Gynecology and Obstetrics (FIGO) was
determined by a gynecologist-oncologist. Histopathology
and tumor grade were reviewed by an independent
pathologist. Tissue selection criteria for this study were
based on a serous histopathology from chemotherapy-
naïve patients and all samples were collected between
1993–2005.
Serous epithelial ovarian tumor tissue array
After a pathological revision of hematoxylin-eosin-stained
slides, three representative cores (0.6 μm diameter) of
each tissue sample, were arrayed on a recipient paraffin
block. The tissue array was composed of 27 BOV, 78 LMPs
and 23 LG tumors (Table 1). This tissue array was then
sectioned, stained with hematoxylin-eosin and received
another pathology review to confirm content. Tumor tis-
sues from the three different institutions did not show sta-
tistically significant differences in protein staining (p >
0.10).
Antibodies
For immunohistochemistry analysis, the following anti-
bodies were used: anti-Ccne1 (sc-198) rabbit polyclonal
antibody, anti-Ccnb1 (GNS1) mouse monoclonal anti-
body (sc-245), anti-Ran goat polyclonal antibody (sc-
1156), anti-Cdc2 (Cdk1) (H-297, sc-747) rabbit polyclo-
nal antibody, anti-p21 (C-19, sc-397) polyclonal anti-
body, anti-TRAIL goat polyclonal antibody (sc-6079),
anti-I2PP2A (Set) goat polyclonal antibody (sc-5655) and
anti-Ref-1 (Ape1) mouse monoclonal antibody (sc-
17774) which were all purchased from Santa Cruz Bio-
technology (Santa Cruz Biotechnology, CA, USA). Specif-
icity of the antibodies was tested by Western blot.
Immunohistochemistry
The tissue arrays, cut in 4 μm sections, were stained by an
immunoperoxidase method as described elsewhere [30].
Tissue sections were heated to 60°C for 30 min, deparaffi-
nized in toluene and rehydrated in an ethanol gradient.
After 3% H2O2 treatment, slides were submerged in either
boiling citrate buffer (0.01 M citric acid adjusted to pH
6.0) (Ape1, Set, Trail, Ccne1, Ran) or EDTA (Cdk1,
Ccnb1, p21) for 15 min., blocked with a protein blocking
serum-free reagent (DakoCytomation Inc., Mississauga,
ON) and incubated with the antibody for 60 min at room
temperature. Tissues were incubated with either a second-
ary biotinylated antibody (DakoCytomation Inc.) or a
rabbit anti-goat biotin-conjugated antibody (1:300) (sc-
2774, Santa Cruz Biotechnology) for 20 min followed by
incubation with streptavidin-peroxidase complex (Dako-
Cytomation Inc.) for 20 min at room temperature. Liquid
diaminobenzidine was applied to visualize the reaction
(DakoCytomation Inc.) and nuclei were counterstained
with hematoxylin. Phosphate buffered saline was used
instead of the primary antibody for negative control. Pro-
tein expression was scored according to the extent (as a
percentage of total malignant cells) and intensity (value of
0 for absence, 1 for low, 2 for moderate, and 3 for high
intensity) of staining based on visualization. These results
were integrated in an algorithm currently used in the liter-
ature (% of cells with high intensity * 100) + ((% of cells
with moderate intensity * 66.66) + (% of cells with low
intensity * 33.33) [30-32]. Peripheral regions of the cores
were not scored to eliminate edge effects. All slides were
independently visualized by light microscopy at 20× mag-
nification and scored in a blind study by two independent
observers with an inter-rating of > 90%. When strong dif-
ferences in scoring between the two observers occurred
the core was re-evaluated to reach a consensus between
the two observers.
Statistical analysis
The association between immunohistochemistry staining
score and tumor classification was analyzed by the Mann-
Whitney U test. Comparisons of grades were performed
between BOV, LMP and LG tumors. Statistical analysis
was performed with SPSS software version 11 (SPSS Inc.,
Chicago, IL, USA) and statistical significance was set at p
< 0.05.
Table 1: Description of the serous tissue array composition
Patientes/samples characteristics Tumor classification
BOV LMP LG
Number of tumors 27 78 23
Number of patients 25 56 18
Mean age ± S.D. (years) 48 ± 16 49 ± 14 52 ± 16
Disease Staging
Stage I - 25 1
Stage II - 3 0
Stage III - 27 15
Stage IV - - 1
no data available 1 1
Peritoneal Implants
no - 35 -
non-invasive - 14 -
invasive - 6 -
Presence of microinvasion
no - 49 -
yes - 7 -
- not applicableBMC Cancer 2008, 8:346 http://www.biomedcentral.com/1471-2407/8/346
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Results
The mean score for expression was defined by the extent
and intensity of immunohistochemistry staining for
Ape1, Set, Trail, Ccne1 Ran, Ccnb1, p21 and Cdk1 (Figure
1). Statistically significant differences in protein expres-
sion were observed for Ccnb1 when BOV (low expres-
sion) were compared to LMP (high expression) tumors (p
= 0.003) (Table 2). Comparing these two classes of
tumors, protein expression of Trail presented a trend
toward significance (p = 0.08) (Table 2). When BOV were
compared to LG TOV tumors, Trail was significantly over-
expressed in the malignant tumor (p = 0.01) (Table 2). LG
TOV tumors presented statistically significant lower level
of p21 compared either with BOV (p = 0.03) or LMP (p =
Protein expression of Trail, p21 and Ccnb1 in serous epithelial benign, low malignant potential and LG ovarian tumors Figure 1
Protein expression of Trail, p21 and Ccnb1 in serous epithelial benign, low malignant potential and LG ovarian 
tumors. Representative images of immunoperoxidase-stained tissue cores are shown for each protein and tumor classes (20× 
magnification). Cytoplasmic and nuclear staining was observed for each of these proteins.BMC Cancer 2008, 8:346 http://www.biomedcentral.com/1471-2407/8/346
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0.001) (Table 2). Finally, a trend toward significance of a
higher expression of Ran in LG TOV compared to LMP
tumors was observed (Table 2).
Some of the LMP tumors exhibited microinvasion (Table
1). Although the number of these cases is small (n = 8), we
noted that LMP samples without microinvasion expressed
higher level of Cdk1 (p = 0.05) compared to those show-
ing microinvasion (data not shown). We also observed
that microinvasive LMP tumors expressed higher levels of
p21 (p = 0.01) and lower levels of Trail (p = 0.05) com-
pared to LG TOV tumors (data not shown). Interestingly,
we noted that expression of p21 was higher in LMP
tumors associated with no (p = 0.02) or non-invasive (p =
0.01) implants compared to the LMP with invasive
implants (data not shown).
Discussion
Only a few studies focus have focused on the molecular
characterizing serous BOV, LMP and LG TOV tumors, but
the biological markers distinguishing between these three
classes of tumors remains to be defined. In our previous
studies, protein expression of selected candidates showed
statistically significant differences between serous LMP
and LG TOVs, although the invasive tumors, due to their
rarity, were under-represented. Based on these results and
the necessity to better understand the relationship
between BOV, LMP and LG TOV epithelial ovarian serous
tumors, we constructed a tissue microarray focusing on
BOV, LMP and LG TOV tumors.
Among all candidate proteins tested (Ape1, Set, Trail,
Ccnb1, Ccne1, Cdk1, p21 and Ran), the most interesting
results were obtained with p21 (Cdkn1a, Waf1, Cip1).
Expression of this protein is highly regulated by p53 and
acts like its effector [37,38]. P21 plays a role in cell cycle
regulation by inhibiting the cyclin dependant kinase
(Cdk) [39,40] [and reviewed in [41,42]]. Low expression
of p21 was observed in many types of cancer including
those of the ovary [34,35,43-47], colon [48], lung [49,50],
head and neck [51], bladder [52], gastric [53],
endometrium [54] and oral cancer [55]. Decreased p21
expression was shown to be inversely associated with the
index of genomic instability in tumor associated with the
worse prognosis to the patient [56,57].
In the present study, statistically significant higher expres-
sion of p21 was observed in BOVs, LMPs or the subgroup
of microinvasive LMPs when compared to LG TOVs.
These results are consistent with those found in the litera-
ture showing that decreased p21 expression was associ-
ated with aggressiveness of the tumors and/or poor
patient prognosis defined by response to chemotherapy,
disease free interval and/or overall survival [34,35,43-46].
However, we were not able to reproduce previous results
showing a significant underexpression of p21 in BOV
compared to LMP tumors [58].
Interestingly, we observed a lower expression of p21 in the
subgroup of LMPs with invasive peritoneal implants that
are known to confer a worse prognosis in term of progres-
sion and overall survival to the LMP patient [27,28]. To
our knowledge, this is the first demonstration of differen-
tial expression of a protein within LMP tumors. These
results support the role of p21 in the aggressiveness and/
or invasiveness of ovarian tumors. However, further stud-
ies would be required in order to increase the number of
these rare samples of LMP presenting invasive implants.
Another differentially expressed protein is Ccnb1. LMP
tumors expressed higher level of Ccnb1 compared to
BOV. This result correlates with those presenting an over-
expression of CCNB1 in highly malignant or poorly differ-
entiated ovarian tumors when monitored by cDNA
microarray analysis [33,35,36,59]. Overexpression of
Ccnb1 was also observed in lung [60,61] and gastrointes-
tinal [62] cancer.
Table 2: Statistical analyses of candidate expression determined by immunohistochemistry and association to tumor class
Protein Significance, Mann-Withney test evaluated with the mean score
BOV-LMP BOV-LG LMP-LG
Ape1 0.13 0.14 0.51
Hmgb2 0.98 0.78 0.59
Set 0.30 0.15 0.30
Trail 0.08 0.01 0.23
Ccnb1 0.003 0.25 0.20
Ccne1 0.20 0.64 0.16
Cdk1 0.19 0.75 0.15
p21 0.83 0.03 0.001
Ran 0.44 0.15 0.10
* bold mean that statistical significance is reached
* italic and bold mean that a trend toward statistical significance is reachedBMC Cancer 2008, 8:346 http://www.biomedcentral.com/1471-2407/8/346
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In our previous studies, we showed statistically significant
differences in the expression of Ape1, Set, Trail, Ccne1 and
Ran between serous LMPs and LG TOVs [30-32] based on
a limited number of samples for the LG tumors. Within
the extended series presented here, only Ran continued to
show a trend toward significance within these LG tumors.
These results demonstrate the importance of validating
candidate markers on the largest possible number of sam-
ples in order to ensure their ability to discriminate
between two groups of tumors. Our previous results,
based on a large set of samples, indicate that Ape1, Set,
Trail, Ccne1 and Ran can discriminate serous LMPs from
high grade TOVs [30-32]. The dualistic model of EOC
tumor development suggests that a large portion of high
grade EOC tumors (G2 and G3) arise from the ovarian
epithelium cells by as yet not clear mechanism implicat-
ing TP53, BRCA1 and/or BRCA2 mutations [63], whereas
the LG TOVs (grade 1) arise from a sequence of unknown
molecular events beginning with the development of
BOV, transitioning through to LMP and MPSC before end-
ing with a LG TOV tumor [63,64]. This continuum is sup-
ported by the fact that serous BOVs and LMPs share
characteristics of LG TOVs as opposed to high grade
tumors. [reviewed in [19,65,66]]. While it would be
tempting to speculate that our combined results support
the dualistic model of tumor progression, we cannot
exclude the possibility that this represents a model where
significant differences could only be seen in higher grade
tumors following tumor progression [13,63]. In line with
this notion, we observe that the protein level of Trail was
significantly lower in BOVs when compared to LG tumors
and tends toward significance when compared to LMPs.
These results combined to our previous study [32] could
suggest an incremental increase of Trail expression from
BOV to LMP, LG, G2 and G3 tumors. These results are in
line with those seen in colon cancer where Trail expres-
sion is lower in adenoma when compared to adenocarci-
noma [67].
Conclusion
In conclusion, we provide one of the few studies that
simultaneously evaluated differential expression of
selected proteins on serous BOV, LMP and LG EOC
tumors. We showed that protein expression of Ccnb1 and
Trail can distinguish BOV from LMP and LG TOVs respec-
tively. We highlight the differential expression of p21
between the LMP without or with non-invasive implants
compared to the more aggressive LMPs presenting inva-
sive implants and suggest that this result be validated in
the future on a larger set of LMPs with invasive implants.
The p21 results may ultimately be useful to identify the
rare poor outcome patient with LMPs and exploited for
the management of these patients.
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